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Background: In critical care patients, reaching optimal b-lactam concentrations poses challenges, as infections
are caused more often by microorganisms associated with higher MICs, and critically ill patients typically have
an unpredictable pharmacokinetic/pharmacodynamic profile. Conventional intermittent dosing frequently yields
inadequate drug concentrations, while continuous dosing might result in better target attainment. Few studies
address cefotaxime concentrations in this population.
Objectives: To assess total and unbound serum levels of cefotaxime and an active metabolite, desacetylcefo-
taxime, in critically ill patients treated with either continuously or intermittently dosed cefotaxime.
Methods: Adult critical care patients with indication for treatment with cefotaxime were randomized to treat-
ment with either intermittent dosing (1 g every 6 h) or continuous dosing (4 g/24 h, after a loading dose of 1 g).
We defined a preset target of reaching and maintaining a total cefotaxime concentration of 4 mg/L from 1 h
after start of treatment. CCMO trial registration number NL50809.042.14, Clinicaltrials.gov NCT02560207.
Results: Twenty-nine and 30 patients, respectively, were included in the continuous dosing group and the inter-
mittent dosing group. A total of 642 samples were available for analysis. In the continuous dosing arm, 89.3%
met our preset target, compared with 50% in the intermittent dosing arm. Patients not reaching this target had
a significantly higher creatinine clearance on the day of admission.
Conclusions: These results support the application of a continuous dosing strategy of b-lactams in critical care
patients and the practice of therapeutic drug monitoring in a subset of patients with higher renal clearance and
need for prolonged treatment for further optimization, where using total cefotaxime concentrations should suffice.
Introduction
Infection in ICUs is an important problem, leading to high anti-
microbial consumption and substantial morbidity and mortality. In
a large, international point-prevalence study, more than half of
patients were considered to have an infection, while 71% were
receiving antibiotics.1 In the critically ill, b-lactams are the most
prescribed group of antibiotics.2
To achieve the best clinical outcome, timely administration of
appropriate antibiotics is critical in ICU patients with severe
infections.3–6 To avoid treatment failure and emergence of anti-
biotic resistance, correct dosing is equally important.7,8 With b-lac-
tams, the bactericidal effect depends on the time the unbound
serum concentration exceeds the MIC of the causative micro-
organism.9 Although, for cephalosporins, preclinical studies show
a bactericidal effect for 60%–70% fT>MIC, clinical data involving
the critically ill suggest a more aggressive approach to achieve
a minimum target of 100% fTMIC is needed to ensure optimal
clinical cure in this vulnerable population.9,10 Optimal dosing in the
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly
cited. For commercial re-use, please contact journals.permissions@oup.com
441
J Antimicrob Chemother 2020; 75: 441–448







niversity Library user on 29 April 2020
individual ICU patient poses challenges as critical illness is associ-
ated with pharmacokinetic (PK) and pharmacodynamic (PD) differ-
ences compared with the non-critically ill.9,11 This patient group is
typically prone to infections with microorganisms associated with
higher MICs.12 Conventional dosing can lead to subtherapeutic lev-
els due to augmented renal clearance in the case of renally cleared
drugs and an increase in the patient’s volume of distribution in the
case of hydrophilic drugs, such as b-lactams.9 Recently, a large
multinational PK point-prevalence study including eight b-lactams
showed that less than half of the patients reached a predefined
preferred PK/PD target. Patients treated for infections in this study
who did not achieve a target of 50% fT>MIC were 32% less likely to
have a positive clinical outcome.13 Conversely, renal dysfunction
can result in elevated antibiotic concentrations and/or accumula-
tion of metabolites.14 Cefotaxime, however, seems to have a high
threshold for (neuro)toxicity.10 The complex PK changes in the crit-
ically ill are outlined in detail in several reviews.9,14,15
Based on their time-dependent profile, continuous as opposed
to intermittent dosing of b-lactams seems a logical alternative in
the ICU population. This concept is supported by PK studies show-
ing better target attainment using a continuous dosing ap-
proach.16–18
In critical care units throughout the Netherlands, b-lactams are
also widely employed in the context of selective decontamination
of the digestive tract (SDD). In an environment with low levels of
antimicrobial resistance, its use is associated with a reduction in
ICU and hospital mortality and ICU-acquired bacteraemia.19 The
SDD approach includes 4 days of preemptive treatment with a
cephalosporin, such as cefotaxime.2
To date, only two observational studies on cefotaxime dosing in
comparable critical care populations are available, both of which
evaluated intermittent dosing.20,21 As cefotaxime is widely pre-
scribed, more knowledge about its PK in ICU patients is important
to ensure best efficacy of the drug. Therefore, the aim of this study
was to ascertain which dosing regimen of cefotaxime results in the
most rapid and persistent target attainment in critically ill patients.
We defined our target as a total (bound and unbound) cefotaxime
concentration of at least 4 mg/L, to be reached within 1 h after
start of treatment and to be maintained during treatment. Both
total (bound and unbound) concentrations and unbound concen-
trations of cefotaxime and its active metabolite desacetylcefotax-
ime were evaluated.
Patients and methods
Study design and patient population
This randomized controlled single-centre study was conducted in a tertiary
referral hospital in the Netherlands between November 2015 and June
2016. The study was approved by the Medical Ethics Board of this hospital
(ethics approval number METc 2014/468, CCMO trial registration number
NL50809.042.14, Clinicaltrials.gov NCT02560207). Enrolment with deferred
consent was used. Written consent was obtained from the patient or next
of kin.
Patients aged 18 years were eligible for inclusion. It was possible to
start cefotaxime (Sandoz B.V., Almere, The Netherlands) per protocol as
part of SDD if a patient had an anticipated mechanical ventilation for >48 h
and ICU stay of >72 h. The duration of treatment was 4 days, or shorter if
the patient was discharged and transferred to a ward within that period, as
SDD including cefotaxime was discontinued on discharge. Exclusion criteria
were: inability to acquire written informed consent; contra-indication for
cefotaxime, such as cephalosporin allergy; no indication for placement of
an arterial line; and use of renal replacement therapy or extracorporeal life
support. Patients were randomized by a research nurse using a secure web
application service provided by the Trial Coordination Center of this hospital.
After randomization, patients were treated with either intermittent dosing
(1 g every 6 h) or continuous dosing (4 g/24 h, after a loading dose of 1 g
infused over 40 min) using a syringe pump (AlarisV
R
GH perfusor; CareFusion,
Rolle, Switzerland). Target attainment was the primary endpoint of this
study and was based on the cefotaxime MIC breakpoint for
Enterobacterales of 1 mg/L, as defined by EUCAST.22 Consequently, we
defined target unbound cefotaxime levels to be at least 1 mg/L. Since 25%–
40% of cefotaxime is bound to plasma proteins, and to allow for a safety
margin due to variability in tissue penetration in ICU patients,14,23 total tar-
get (protein-bound and unbound) cefotaxime levels were defined as 4 mg/
L and higher, at any given timepoint during treatment.
Data collection
Blood samples were drawn from an indwelling arterial catheter, placed for
routine monitoring. In patients randomized for continuous administration,
2 mL blood samples were drawn on Day 1 at 0 min, then at 40 min from
start of infusion of the loading dose, i.e. immediately after completion of
the loading dose. Subsequent samples were drawn at 1, 2, 4, 8, 12 and 24 h
after start of administration on Day 1. During the subsequent days of con-
tinuous infusion, samples were drawn every 12 h, until the end of treatment
on Day 4. In patients randomized for intermittent dosing, 2 mL blood sam-
ples were drawn on Day 1 at 0 min, directly after infusion at 40 min, 1, 2, 4,
8, 12 and 24 h after start of administration on Day 1. After that, trough and
peak levels were obtained once daily just before and 40 min after bolus in-
fusion, respectively, until the end of treatment. Samples were centrifuged
and serum was frozen at #80C, until analysis. Patient characteristics
included demographic and clinical data, assessment of severity of illness
reflected by the APACHE IV score and laboratory investigations. Baseline
was considered start of cefotaxime treatment.
PK analysis
Plasma concentrations of cefotaxime (total and unbound) and both total
and unbound concentrations of its active metabolite desacetylcefotaxime
were determined at the laboratory of the Department of Clinical Pharmacy
and Pharmacology of University Medical Center Groningen by means of a
validated analytical method using LC-MS/MS. In brief, cefotaxime and desa-
cetylcefotaxime were analysed by means of an isotope dilution method. As
internal standard, a stable isotope of cefotaxime was used. LC-MS/MS
equipment (Thermo Fisher Scientific, Waltham, USA) consisted of a
Vanquish UPLC pump, autosampler, column compartment and Quantiva
triple quadrupole mass spectrometer. Total cefotaxime and desacetylcefo-
taxime concentrations were measured after protein precipitation of the
samples; free cefotaxime and desacetylcefotaxime were measured after
temperature-controlled ultrafiltration of the samples using Nanosep 30K
Omega Centrifugal Devices (Pall Life Sciences, Portsmouth, UK) and meas-
uring cefotaxime and desacetylcefotaxime in the ultrafiltrate. The lower
limit of quantitation of both cefotaxime and desacetylcefotaxime was
1 mg/L and the method was linear up to 200 mg/L for cefotaxime and up to
100 mg/L for desacetylcefotaxime. The assay complied with the criteria for
bioanalytical method development as issued by the EMA.24 Target attain-
ment was assessed by comparing measured concentrations with our pre-
set target as described above; target attainment was thus defined by
reaching a target of at least 4 mg/L for total cefotaxime and at least 1 mg/L
for unbound cefotaxime within 1 h after start of treatment, and maintain-
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Statistical analysis
Target attainment was presented as percentage of time above target per
subject and the percentage reaching the target at group level. Continuous
parameters such as age, weight, height, length of stay (LOS) and duration
of mechanical ventilation were collected and depicted in absolute figures
and medians, including IQR. Non-normally distributed continuous variables
were compared by Mann–Whitney U-test for unpaired data. Categorical
data, which were depicted as proportions, were compared using the v2 test
or Fisher’s exact test (two-sided; type I, 5%). PK analysis was performed
with and without correction for outliers and apparent permutations (trough
level taken as peak level and vice versa). Outliers, assumed to have been
caused by procedural shortcomings such as sampling during bolus infusion,
were defined as higher than 3% the IQR above Q3 and lower than 3% below
Q1. SPSS v 23.0 (IBM Corp., Armonk, NY, USA) and MinitabV
R
18.1 (VC 2017
Minitab, Inc.) were used for statistical analyses and graphics.
Power calculation
Based on available literature on b-lactam antibiotics, we expected continu-
ous dosing to result in adequate drug levels in 80% of patients, compared
with 40% of patients in the intermittent group.17 Therefore, our sample size
(taking into account an absolute effect size of 40%, an alpha of 0.05 and a
beta of 0.8) was 23 patients per group. Correcting for potential dropout, we
aimed for 30 patients per group.
Results
Demographic data and clinical characteristics
Two-hundred and eight patients were deemed eligible for inclu-
sion. Of these, 128 were excluded from randomization; 111 be-
cause admission occurred out of office hours and a research nurse
was not available, 12 because inclusion criteria were not met and
5 were missed at screening. Eighty ICU patients were screened for
eligibility and were randomized for treatment with continuous or
intermittent dosing. Consent could not be obtained from 11
patients, 5 patients were excluded because of breach of protocol,
such as wrong dosing, 2 patients died shortly after admittance, 1
patient had no indication for an arterial line, 1 patient received
cefotaxime only very briefly and 1 patient did not receive cefotax-
ime. We thus included 59 patients for analysis; 29 in the continu-
ous dosing arm and 30 in the intermittent dosing arm. Patient
characteristics are shown in Table 1. Of the total group, most of the
patients were middle-aged and male, with a median LOS in the
ICU of 6 days and with a median APACHE IV score of 70. Weight
and BMI were significantly different between the continuous and
intermittent groups, with the heavier patients in the intermittent
group.
PK data
After correction for outliers (n=15), 627 samples from 59 patients
could be analysed (327 samples from 29 patients and 300 sam-
ples from 30 patients in the continuous group and the intermittent
group, respectively); 271 and 247 samples were available from 1 h
after start of treatment in the continuous group and the intermit-
tent group, respectively. The median number of samples per
patient was 11 (IQR=9–14) for the continuous group and 10
(IQR=7–13) (not significant) for the intermittent group (Table S1,
available as Supplementary data at JAC Online). For total cefotax-
ime concentrations, the target of 4 mg/L was reached within 1 h
after start of treatment and maintained thereafter in 89.3% of
patients in the continuous versus 50% of patients in the intermit-
tent arm (P=0.003) (Figure 1 and Table S2). From 1 h after start of
treatment, 266 of 271 (98.2%) available samples in the continuous
group had a cefotaxime concentration4 mg/L, versus 194 of 247
(78.5%) samples in the intermittent group (P<0.0001). For un-
bound cefotaxime concentrations, the target of 1 mg/L was
reached and maintained in 96.4% of patients in the continuous
arm versus 71.4% in the intermittent arm (P=0.025) (Figure 2 and
Table S3). Comparing all available concentration measurements
from 1 h after start of treatment per group, median total cefotax-
ime, unbound cefotaxime, total desacetylcefotaxime and un-
bound desacetylcefotaxime concentrations were all significantly
higher in the continuous group compared with the intermittent
group (Figures 1–3 and Table S4). In patients not reaching our
predefined target, creatinine clearance on ICU admittance was
significantly higher than in patients who did reach this target.
APACHE IV score, albumin concentration or BMI on ICU admittance
were not associated with target attainment (Table 2).
Discussion
Our randomized controlled study assessing total and unbound
cefotaxime, as well as total and unbound desacetylcefotaxime
concentrations in a heterogeneous group of ICU patients, showed
that continuous dosing of cefotaxime in adult critical care patients
will lead to better PK target attainment compared with intermit-
tent dosing.
Our results are in line with available literature.17,25 In a pro-
spective, double-blind, randomized controlled trial, Dulhunty
et al.17 compared PK and clinical outcome in 60 patients with se-
vere sepsis allocated to treatment with a b-lactam antibiotic
(piperacillin/tazobactam, meropenem or ticarcillin/clavulanate)
through either continuous or intermittent dosing. Plasma antibiotic
concentration exceeded a predefined MIC (based on breakpoints
for Pseudomonas aeruginosa; free plasma antibiotic concentra-
tions of 16 mg/L for piperacillin and ticarcillin, 2 mg/L for merope-
nem) in 82% of patients in the continuous arm versus 29% in the
intermittent arm. Survival and ICU-free days did not significantly
differ between the groups. As a wide array of targets and dosing
schedules are employed, comparing PK studies on b-lactam dos-
ing is complex. However, overall, as summarized in a recent review
by Veiga and Paiva,25 continuous dosing seems to result in better
PK results compared with intermittent dosing. Moreover, a better
clinical outcome using prolonged or continuous infusion in the crit-
ically ill is suggested in several recent meta-analyses.26–29 A large
multicentre randomized controlled trial powered on mortality
comparing continuous with intermittent dosing of b-lactams is
currently recruiting patients.30 To date, only a few studies on cefo-
taxime dosing in comparable cohorts of ICU patients have been
published. Seguin et al.20 assessed plasma and peritoneal levels of
cefotaxime and its metabolite in 11 patients with secondary peri-
tonitis treated with 4 g of cefotaxime daily through continuous in-
fusion, following a bolus of 2 g. Although wide interpatient
variation was found, this regimen provided a peritoneal concentra-
tion of >5% MIC for the recovered Enterobacteriaceae and the sus-
ceptibility breakpoint of cefotaxime for facultative Gram-negative
microorganisms. In a prospective, open-label, non-randomized
setting, Abhilash et al.21 examined plasma concentrations of
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cefotaxime in 30 critically ill patients treated with 1 g of cefotaxime
three times daily infused over 30 min. Cefotaxime levels were
found to be below the MIC and <5% MIC for the isolated microor-
ganisms in 16.7% and 43.3% of patients, respectively.
The patients in our cohort who did not reach our target had
higher creatinine clearance. Augmented renal clearance is a recog-
nized risk factor for underdosing of b-lactams.31,32
Strengths of our study are that we used a randomized con-
trolled design and recruited typical ‘real-life’ ICU patients. We used
dense sampling to allow for a precise assessment of the difference
in target attainment. Furthermore, we also assessed unbound
concentrations and the active metabolite desacetylcefotaxime to
explore differences in drug metabolism. However, as the antibac-
terial activity of desacetylcefotaxime is 4–8-fold less than
Table 1. Demographic data and clinical characteristics
Variable total continuous intermittent P
Number of patients 59 29 30
Male/female, n/n (%/%) 39/20 (66/34) 20/9 (69/31) 19/11 (63/37) 0.648
Age (years), median (IQR) 67 (56–77) 67 (60.5–74) 66.5 (45.25–78.25) 0.808
Height (cm), median (IQR) 175 (170–185) 175 (171–185) 175 (168.25–185) 0.503
Weight (kg), median (IQR) 82 (74–97) 77 (70–93.50) 85.50 (75.75–101.25) 0.05
BMI (kg/m2), median (IQR) 26.6 (24.5–30.9) 25.4 (22.7–28.9) 28.9 (24.5–32.2) 0.04
LOS in the ICU at the start of cefotaxime
treatment (days), median (IQR)
1 (0–1) 1 (0–1.5) 1 (0–1) 0.315
Duration of cefotaxime (days), median (IQR) 4 (3–5) 4 (3–5) 4 (3–5) 0.106
Patient category, n (%) 59 (100) 29 (100) 30 (100) 0.362
medical 17 (28.8) 7 (24.1) 10 (33.3)
surgical 20 (33.9) 9 (31) 11 (36.7)
trauma 4 (6.8) 1 (3.4) 3 (10)
neurological 6 (10.2) 5 (17.2) 1 (3.3)
other 12 (20.3) 7 (24.1) 5 (16.7)
Acute/planned admission, n/n (%/%) 15/44 (25.4/74.6) 9/20 (31/69) 6/24 (20/80) 0.33
APACHE IV score, median (IQR) 70 (53–93) 71 (57.5–95.5) 67.5 (49.5–90.75) 0.422
Vasopressor use—yes/no, n/n (%/%) 31/28 (53/47) 16/13 (55/45) 15/15 (50/50) 0.446
Fluid resuscitation—yes/no, n/n (%/%) 35/24 (59/41) 19/10 (66/34) 16/14 (53/47) 0.246
Mechanical ventilation—yes/no, n/n (%/%) 50/9 (85/15) 24/5 (83/17) 26/4 (87/13) 0.478
Serum albumin (g/L), median (IQR) 30 (26–35) 30 (26–34) 30.5 (26–36) 0.470
Serum creatinine (lmol/L), median (IQR) 81 (70–107) 84 (68–107) 80.5 (70–109) 0.617
Serum ALT (U/L), median (IQR) 27 (13–57) 21 (11.5–51.5) 37.5 (20.75–63.75) 0.089
Urinary creatinine 24 h (mmol/24 h), median (IQR) 9 (7–13) 9 (6.1–12.5) 10 (7.75–14) 0.186
Creatinine clearance (mL/min), median (IQR) 80 (49–112) 75 (42.5–99.5) 84 (56.5–134.25) 0.214
LOS in the ICU (days), median (IQR) 6 (4–10) 6 (4–10.5) 6.5 (3–10.25) 0.483
ICU mortality, n (%) 10 (16.9) 4 (13.8) 6 (20) 0.731






































































niversity Library user on 29 April 2020
cefotaxime and its contribution to the total concentration is low,
we chose not to integrate the desacetylcefotaxime concentrations
in the analysis of total cefotaxime concentration.33 In our cohort,
we did not find accumulation of desacetylcefotaxime (Table S4). As
expected, comparing the two treatment arms, results from the
total and unbound concentrations of cefotaxime and desacetylce-
fotaxime were comparable, with higher median concentrations in
the continuous dosing arm. As the free fraction percentage of cefo-
taxime appeared to have a low range in our cohort of heteroge-
neous critical care patients (Table S4), measurements of total
cefotaxime concentrations for therapeutic drug monitoring (TDM)
purposes should suffice. While not yet a standard procedure in
many centres, the use of TDM in optimization by personalizing anti-
biotic dosing of b-lactams in the critical care population is gaining
ground.10,25,34,35 Although evidence for a reduction in mortality is
lacking thus far,34 the use of TDM has proven to lead to better PK
target attainment36 and might be especially useful in patients with
high PK variability such as those with higher renal clearance10,25
who are to be treated for a longer period of time; in our cohort, with






























































Figure 2. Boxplot of unbound cefotaxime concentration, per timepoint, per treatment group.
Table 2. Baseline characteristics in patients who did and did not reach and maintain a total cefotaxime target concentration of 4 mg/L
Baseline characteristic Target reached (n=39) Target not reached (n=17) Pa
Albumin (g/L), median (IQR) 29 (26–34) 32 (28–39.5) 0.112
APACHE IV score, median (IQR) 73 (54–97) 61 (43.5–91.5) 0.121
BMI (kg/m2), median (IQR) 25.7 (24.5–30.3) 27.5 (23.5–33.8) 0.354
Creatinine clearance (mL/min), median (IQR) 65 (30–99) 114 (84–173) 0.000
Data on target attainment available for 28 of 29 (96.6%) patients in the continuous group and for 28 of 30 (93.3%) patients in the intermittent group.































































Figure 3. Boxplot of total desacetylcefotaxime concentration, per timepoint, per treatment group.
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Higher dosing in this category could be an alternative strategy to
obtain better target attainment when TDM is not available.10
This study also has some limitations. Although, for b-lactams, a
%fT>MIC between 40% and 70% for a bactericidal effect is described
in earlier in vivo studies,7 and different targets have been
assessed,13 a target of an unbound concentration of at least 4%
the MIC for 100% of the time is considered optimal and this target
is advocated in several recent publications.6,10,25 Based on these
recommendations, our target (100% fT>MIC) can be considered
somewhat conservative. Applying the strictest target of 100%
fT>4%MIC to our data, 82.4% versus 23.3% of patients would reach
this target from 1 h after start of treatment in the continuous and
intermittent arms, respectively (Table S5). Inclusion was feasible
during office hours only. This might have created a selection bias
for the study population, but not for allocation to the treatment
arms. As this study was carried out in a single-centre setting and
patients with renal replacement therapy or extracorporeal life sup-
port were excluded, our results might not be generalizable to all
critical care patients. After careful consideration of the small sam-
ple size and heterogeneous nature of the population, we chose not
to include clinical outcome, as we felt the results would not be sup-
ported by an adequately powered study. A large randomized con-
trolled trial with clinical outcome as endpoint is on its way.30
Baseline characteristics such as creatinine clearance and serum al-
bumin concentration were evaluated at start of treatment and not
over time. The baseline weight and BMI were significantly higher in
the intermittent-dosing treatment group. Obesity as a risk factor
for underdosing is recognized in some studies,37–39 but not sup-
ported by other publications.40,41 In our study, we did not find such
an association. Some results were excluded from analysis, as they
were identified as outliers, and some results were apparent permu-
tations. Results of an analysis including these data points did not
alter our main results (Tables S6–S10 and Figure S1). As cefotaxime
was prescribed as preemptive antimicrobial treatment in the con-
text of SDD, we used a presumptive MIC as issued by EUCAST.
Target non-attainment would occur more often in the intermittent
group at higher MIC targets (Tables S5 and S11 and Figure 4).
Conclusions
In our cohort of 59 patients, continuous dosing resulted in higher
median total and unbound cefotaxime and desacetylcefotaxime
levels, and our predefined target was met more often in the con-
tinuous dosing group. Patients who did not reach this target had
higher creatinine clearance. Our study endorses a continuous dos-
ing strategy of b-lactams in the challenge to optimize control of in-
fectious problems in the vulnerable critical care population. In a
selected patient subgroup with augmented renal clearance, higher
dosing is indicated. TDM based on total cefotaxime concentrations
could further optimize treatment in cases where prolonged treat-
ment is indicated.
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